Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
BP4 S.r.l., a ten percent owner of Milestone Scientific Inc. (NASDAQ:MLSS), a $37.16 million market cap company whose shares have declined over 50% in the past six months, has sold 19,210 shares of common stock on October 3, 2025. The shares were sold in two transactions at prices ranging from $0.4491 to $0.45, netting a total of $8,636.
Following the transactions, BP4 S.r.l. directly owns 9,235,384 shares of Milestone Scientific Inc.
The sales were reported in a Form 4 filing with the Securities and Exchange Commission. The filing was signed by Dr. Pedro Palau, Liquidator, on October 8, 2025.
In other recent news, Milestone Scientific reported its Q2 2025 financial results, which showed a slight miss in earnings and a revenue shortfall against projections. The company’s earnings per share came in at a loss of $0.02, compared to the forecasted loss of $0.01, while revenue was $2.3 million, below the expected $2.6 million. Benchmark has maintained its Speculative Buy rating on Milestone Scientific, with a price target of $1.25, highlighting progress in the Medicare market for its CompuFlo System. The company ended the second quarter with $1.3 million in cash and no debt, and it has secured coverage from three of the twelve Medicare Administrative Contractors for its pain management system. Additionally, Milestone Scientific has appointed Dr. Dawood Sayed, a leader in pain medicine, to its Board of Directors. Dr. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center. These developments indicate ongoing strategic moves by the company in its market segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.